Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.” The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number following the reverse stock split will be 114082 308.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>

>;elm:context_link;itc:0;sec:content-canvas" href="https://www.tipranks.com/screener/top-insider-trading-stocks/?type=stockAnalysisLanding&utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">See Insiders’ Hot Stocks on TipRanks >>

Read More on ERNA:

Disclaimer & DisclosureReport an Issue

• Eterna Therapeutics Completes $6M Private Placement

• Eterna Therapeutics Increases Authorized Shares and Amends Bylaws

• Ernexa Therapeutics announces new data to be presented at ASCO meeting 2025

• Ernexa Therapeutics establishes Texas subsidiary

• Ernexa Therapeutics presents data on cell therapy treatment at AACR meeting